ID   1A9/T80
AC   CVCL_CZ93
SY   1A9 T80; 1A9T80
DR   cancercelllines; CVCL_CZ93
DR   GEO; GSM95438
DR   Progenetix; CVCL_CZ93
DR   Wikidata; Q54582666
RX   PubMed=16382445;
CC   Population: African American.
CC   Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol).
CC   Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line).
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
DI   NCIt; C7979; Ovarian endometrioid adenocarcinoma
DI   ORDO; Orphanet_454723; Endometrioid carcinoma of ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_H619 ! A2780-1A9
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 05-10-23; Version: 11
//
RX   PubMed=16382445; DOI=10.1002/gcc.20300;
RA   Wang Y.C., Juric D., Francisco B., Yu R.X., Duran G.E., Chen G.K.,
RA   Chen X., Sikic B.I.;
RT   "Regional activation of chromosomal arm 7q with and without gene
RT   amplification in taxane-selected human ovarian cancer cell lines.";
RL   Genes Chromosomes Cancer 45:365-374(2006).
//